Analytical Data
-
基因名
HLA-A*02:01&B2M&AFP(PLFQVPEPV)
- Application
-
别名
Alpha-fetoprotein; Alpha-1-fetoprotein; Alpha-feto; AFP; HPAFP; AFPD; FETA; MHC
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
A0A140T913 (G25-T305)&P61769
-
表达区间
A0A140T913 (G25-T305)&P61769 (I21-M119)&PLFQVPEPV
-
氨基酸序列
GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWEPSSQPT&IQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM&PLFQVPEPV
-
分子量
55-60 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the recombinant protein HLA-A*02:01 in conjunction with β2-microglobulin (B2M) and alpha-fetoprotein (AFP, specifically the peptide PLFQVPEPV) is grounded in the exploration of immune response mechanisms, particularly in cancer immunotherapy. HLA-A*02:01 is one of the most common human leukocyte antigen (HLA) alleles, playing a pivotal role in presenting tumor-associated antigens to cytotoxic T cells. AFP, often associated with liver cancer and other malignancies, serves as a potential target for immunotherapy due to its aberrant expression in tumors. The peptide PLFQVPEPV, derived from AFP, has been identified as a candidate for T-cell recognition, which is crucial for developing effective cancer vaccines. By recombining HLA-A*02:01 with B2M and the AFP peptide, researchers aim to create a stable and effective presentation complex that can elicit a robust cytotoxic T lymphocyte (CTL) response against AFP-expressing tumors. This research not only aids in understanding the nuances of antigen presentation but also paves the way for innovative therapeutic approaches for AFP-positive cancers, highlighting the potential for personalized medicine in oncology.
